Arab & Middle East News
(ARABNEWSWIRE.COM, September 13, 2017 ) As the second largest internal organ, liver performs many complex functions in the body (bile secretion, toxin removal, and fighting infections, etc.). Malfunctioning of liver can be life-threatening as it can cause multiple acute and chronic diseases (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumour, and liver cirrhosis, among others). The initial symptoms of liver damage include nausea, fatigue, diarrhoea, jaundice, swollen abdomen, and mental disorientation among other. Sub-Saharan African region is highly affected by hepatitis B, where 5%-10% of population is chronically infected putting people of the region at a high risk of cirrhosis and liver cancer. In Middle-East, approximately 2%-5% of population is chronically infected with hepatitis disease.
View Full Report @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-liver-disease-treatment-market-1738/
The growth of Liver Disease Treatment market is majorly driven by factors unorganized lifestyle, rising public awareness, growth in geriatric population, and unmet needs for the treatment of liver cancer. Additionally, spur in demand for alcohol has increased the risk of liver cirrhosis. According to World Health Organization, alcohol consumption is anticipated to cause 20% to 50% of cirrhosis of the liver. Also, growing obese population has also increased the risk of non-alcoholic fatty liver disease which is caused by build-up of fat in the liver. The obese population has doubled since 1980. In 2014, approximately 13% of the world’s population, that is, more than 600 million adults were obese as per World Health Organization. The key restraints of the market are complex drug approval procedure, side-effects of the product (fatigue, fever, and depression), and expensive treatment cost.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-liver-disease-treatment-market-1738/request-sample
Middle-East & Africa Liver Disease Treatment Market is segmented on the basis of Treatment Modality and Disease Type. Based on Treatment Modality, the market is classified into Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids, and Others. On the basis of Disease Type, the market is classified into Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol Induced, Liver Cancer, and Others
Inquire before buying @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-liver-disease-treatment-market-1738/inquire
The major companies dominating Middle-East & Africa Liver Disease Treatment Market are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany), and AstraZeneca (United Kingdom).
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast